Braveheart Bio (BRVE) News
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
20.39+1.12 (+5.81%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BRVE news summary
We found 6 recent headlines mentioning Braveheart Bio (BRVE): 0 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Seeking Alpha. BRVE is making an outsized move today, up 5.81% at $20.39, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Braveheart Bio, Inc. GAAP EPS of -$0.51 misses by $0.07", was published by Seeking Alpha on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Braveheart Bio headlines
- Braveheart Bio, Inc. GAAP EPS of -$0.51 misses by $0.07Seeking Alpha
- Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimenGlobeNewswire
- Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in LondonSAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…GlobeNewswire
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeksGlobeNewswire
- Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…GlobeNewswire
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…GlobeNewswire